Evidence map›Paper›PMID 35012554›Full record

ArticleJournal of nanobiotechnology2022

Bone mesenchymal stem cell-derived exosomal microRNA-7-5p inhibits progression of acute myeloid leukemia by targeting OSBPL11.

Duanfeng Jiang, Xin Wu, Xiaoying Sun, Wei Tan, Xin Dai, Youbang Xie, Ashuai Du, Qiangqiang Zhao

RetractedAbstract readRetracted Publication
In one paragraph

Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Duanfeng Jiang *Department of Hematology, Second Affiliated Hospital of Hainan Medical College, Haikou, 570311, People's Republic of China.
Xin Wu *Department of Orthopedics, Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China.
Xiaoying Sun *Nursing School, Soochow University, Suzhou, 215000, People's Republic of China.
Wei TanDepartment of Orthopedics, Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China.
Xin DaiDepartment of Hematology, The Qinghai Provincial People's Hospital, Xining, 810007, People's Republic of China.
Youbang XieDepartment of Hematology, The Qinghai Provincial People's Hospital, Xining, 810007, People's Republic of China.
Ashuai DuDepartment of Infectious Diseases, Guizhou Provincial People's Hospital, Guiyang, 550002, People's Republic of China. 214515395@qq.com.
Qiangqiang ZhaoDepartment of Hematology, The Qinghai Provincial People's Hospital, Xining, 810007, People's Republic of China. zgxyws@163.com.

Funding

Fundamental Research Funds for Central Universities of the Central South University 2019zzts366Fundamental Research Funds for Central Universities of the Central South University 2020zzts896guiding project of Qinghai Provincial Health and Family Planning Commission 2018-wjzdx-17Project of Kunlun Elite, High-End Innovation and Entrepreneurship Talents of Qinghai Province 2021
6 · The paper itself

Abstract

backgroundAcute myeloid leukemia (AML) is a malignant clonal disease of hematopoietic stem- and progenitor-cell origin. AML features massive proliferation of abnormal blasts and leukemia cells in the bone marrow and the inhibition of normal hematopoiesis at onset. Exosomes containing proteins or nucleic acids are secreted by cells; they participate in intercellular communication and serve as key modulators of hematopoiesis. The purpose of this study was to investigate the effects of exosomes derived from bone marrow mesenchymal stem cells (BMSCs) on the regulation of AML and the underlying mechanisms mediated by microRNA (miRNA).

methodsDysregulated miR-7-5p in AML patients was identified using qRT-PCR and its clinical significance was explored. Bioinformatic analysis revealed the target gene OSBPL11 that could be regulated by miR-7-5p. The findings were validated using a dual-luciferase reporter assay and western blotting. The functional genes of the PI3K/AKT/mTOR signaling pathway were identified, and the functional significance of miR-7-5p in AML cells was determined using a functional recovery assay. AML cells were co-cultured with exosomes originating from BMSCs overexpressing miR-7-5p to determine cell-cell regulation by Exo-miR-7-5p, as well as in vitro and in vivo functional validation via gain- and loss-of-function methods.

resultsExpression of miR-7-5p was decreased in AML patients and cells. Overexpression of miR-7-5p curbed cellular proliferation and promoted apoptosis. Overexpression of OSBPL11 reversed the tumorigenic properties of miR-7-5p in AML cells in vitro. Exo-miR-7-5p derived from BMSCs induced formation of AML cells prone to apoptosis and a low survival rate, with OSBPL11 expression inhibited through the PI3K/AKT/mTOR signaling pathway. Exo-miR-7-5p derived from BMSCs exhibited tumor homing effects in vitro and in vivo, and inhibited AML development.

conclusionsExo-miR-7-5p derived from BMSCs negatively regulates OSBPL11 by suppressing the phosphorylation of the PI3K/AKT/mTOR signaling pathway, thereby inhibiting AML proliferation and promoting apoptosis. The data will inform the development of AML therapies based on BMSC-derived exosomes.

Indexed as

Leukemia, Myeloid, AcuteAnimalsCell Line, TumorExosomesFemaleHumansMesenchymal Stem CellsMiceMicroRNAsOxysterol Binding ProteinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptors, SteroidTOR Serine-Threonine KinasesMicroRNAsMIRN7-1 microRNA, humanMTOR protein, humanOxysterol Binding ProteinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptors, SteroidTOR Serine-Threonine KinasesAcute myeloid leukemiaBone marrow mesenchymal stem cellsExosomemiR-7-5pOSBPL11PI3K/AKT/mTOR

Identifiers

PMID35012554
PMCPMC8744354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.